|
|
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Research
General Research
- Non-Nucleoside Reverse Transcriptase Inhibitors in Development (March 18, 2008)
To read PDF, click here
From AIDS InfoNet
- Drug Watch: Next-Generation NNRTIs: Etravirine and Rilpivirine (Winter 2008)
To read PDF, click here
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- NNRTIs: The Next Generation Approaches (Part I) (December 14, 2006)
From The Body PRO
- NNRTIs: The Next Generation Approaches (Part II) (December 14, 2006)
From The Body PRO
- HIV JournalView: Adherence, Viral Fitness and NNRTI and PI Resistance (February/March 2006)
Bangsberg et al find that NNRTIs are more likely to suppress HIV than a single PI, but are also more vulnerable to resistance at low adherence levels.
From The Body PRO
- HIV JournalView: Dosing Adjustment Likely Needed for Statins Taken With NNRTIs (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- HIV JournalView: Low-Level Viremia May Slowly Breed Resistance, but Watch Out for NNRTIs (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- News Flash!! Once-a-Day Triple NRTI Warning (October 27, 2003)
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
- New Anti-HIV Therapies: New NNRTIs (January 2003)
From Project Inform
- The Clinical Relevance of Non-Nucleoside Reverse Transcriptase Inhibitor Hypersusceptibility: A Prospective Cohort Analysis (July 11, 2002)
In The XIV International AIDS Conference, from The Body PRO
- In Routine Practice, the Durability of First-Line HAART Is Better for NNRTI Than PI-Based Regimens, Regardless of Baseline HIV Status (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
- New Insights Into Mechanisms of HIV-1 Resistance to Reverse Transcriptase Inhibitors (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Distinguishable Lipid Profiles Between PI and NNRTI Therapy May Carry Different Risk of Cardiovascular Disease (CVD) (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Associations Between Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Use and HIV-Associated Lipodystrophy Syndrome (HALS) in the Dagna-LipART Cohort Study (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Experimental NNRTI Drugs (Spring 2001)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Safety of Non-PI-containing Regimens in People With High Viral Loads (August 17, 2000)
In STEP Ezine, from Seattle Treatment Education Project
- Patient Adherence With Twice-Daily Dosing of Nelfinavir Equivalent to NNRTIs When Given in Combination With Dual NRTIs (July 13, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Primary Infection with HIV-1 with Reduced Drug Susceptibility Does Not Appear to Result from Point Source Transmission (January 31, 2000)
In The 7th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Reduced Susceptibility to NRTI Is Associated With NNRTI Hypersensitivity in Virus From HIV-1-Infected Patients (January 31, 2000)
From Seattle Treatment Education Project
- Trials & Errors: Studies Look at Which Combinations Are Better (February 1999)
Clinical trials using NNRTIs with or instead of protease inhibitors.
From Seattle Treatment Education Project
Efavirenz (Sustiva, Stocrin)
- Combining Sustiva + Viread May Increase Liver Risk, Case Reports Suggest (May 9, 2008)
In aidsmap.com
- Sustiva Study Finds Ethnicity, Quality of Life Predict Treatment Outcomes (April 1, 2008)
From Project Inform
- High LDL Cholesterol Levels May Drop by Switching Sustiva to Viramune, Study Says (June 12, 2007)
From AIDSMeds.com
- Metabolic Complications: A CROI Round-Up (February 28, 2007)
Includes an analysis of research examining lopinavir/ritonavir vs. efavirenz, the use of growth hormone releasing factor to treat fat gain, the link between cardiovascular disease and HIV treatment, the use of ezetimibe (a choleserol-reducing agent) and the latest on bone health in HIV-infected patients.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Baseline NNRTI Resistance and Virologic Failure in Treatment-Naive Patients on Efavirenz: An Interview With Daniel Kuritzkes, M.D. (February 26, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Efavirenz-Based Regimens Best Lopinavir/Ritonavir Regimens in Head-to-Head Trial (August 17, 2006)
In XVI International AIDS Conference
- ACTG 384 Substudy: DEXA Outcomes in Antiretroviral-Naive Patients Randomized to Efavirenz or Nelfinavir or Both Plus Nucleoside Backbone (August 16, 2006)
In XVI International AIDS Conference
- Data Supports Bioequivalence for Once-Daily, Single-Pill, Fixed-Dose Combination of Sustiva and Truvada, Drug Companies Announce (January 9, 2006)
Filing of a new drug application is expected in the second quarter of 2006.
To read PDF, click here
From Bristol-Myers Squibb Company and Gilead Sciences, Inc.
- HIV JournalView: Dosing Adjustment Likely Needed for Statins Taken With NNRTIs (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- HIV JournalView: Efavirenz Has No Significant, Lasting Impact on Neuropsychological Performance (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- Higher Efavirenz Plasma Levels May Increase Neuropsychiatric Complication Risk (December 15, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Efavirenz Clearance May Take Up to 8 Weeks, Case Report Warns; Implications for Treatment Interruption (September 28, 2005)
From aidsmap.com
- Gilead's Fixed-Dose Combination of Truvada + Efavirenz Not Yet Bioequivalent to Drugs Alone (August 10, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Head-to-Head Comparison of Three Backbone Regimens With Efavirenz (July 27, 2005)
Although this study finds no clear winner, the abacavir + ddI arm appears to fall a bit short.
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Efavirenz Reduces Plasma Levels of Popular Statins (July/August 2005)
From The Body PRO
- Neuropsychiatric Symptoms From Efavirenz Not Always Time-Limited (May/June 2005)
More than half of 120 Spanish patients report persistent, though usually mild, symptoms after nearly two years.
From The Body PRO
- Dual NRTI Plus Efavirenz Regimen Superior to Boosted PI Plus Efavirenz (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Multi-National Trial Confirms Superiority of 3-Drug Regimen Containing Efavirenz for the Treatment Naive (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The Genomics of Efavirenz Toxicity (January 2005)
Part of HIV JournalView's Top 10 Research Reports of 2004.
In The 12th International AIDS Conference, from The Body PRO
- Atazanavir Has Similar Efficacy, Safety to Efavirenz (August 2, 2004)
Unlike most protease inhibitors, atazanavir appears not to increase cholesterol, triglycerides or blood-sugar levels, potentially making it a more attractive option for people at risk of developing cardiovascular disease, a Phase III study finds.
From aidsmap.com
- Tenofovir and Efavirenz Show Promise as Two-Drug Maintenance Regimen (July 26, 2004)
The so-called "COOL Study" examined this novel two-drug regimen in patients who had already achieved viral suppression on traditional, three-drug HAART.
From aidsmap.com
- HDL Benefit Is Maintained With Extension of Nevirapine and Efavirenz Treatment in 2NN Study (July 14, 2004)
In The XV International AIDS Conference, from The Body PRO
- Genetics, Race/Ethnicity and Efavirenz Side Effects (July 2004)
A study finds that a genetic variation, more common among African Americans than whites, impacts the body's absorption of efavirenz.
To read PDF, click here
In Project Inform Perspective, from Project Inform
- Some Reverse Transcriptase Mutations May Increase Susceptibility to Efavirenz-Based Regimens (July 2004)
Abstract of a study published in the Journal of Infectious Diseases.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Triple-Nucleoside Regimens Versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection (April 29, 2004)
Abstract of results from ACTG 5095, finding Trizivir (AZT/3TC/abacavir) to be far less effective at suppressing viral load than regimens consisting of efavirenz (Sustiva) plus two or three NRTIs.
In New England Journal of Medicine
- Efavirenz and Nevirapine Keep Going, and Going and Going ... (March/April 2004)
Efavirenz and nevirapine may persist in the body longer than was originally thought according to two studies presented at CROI 2004.
In Positively Aware, from Test Positive Aware Network
- Efavirenz May Reduce Blood Levels of Cholesterol Drugs (March/April 2004)
A study presented at CROI 2004 suggests an interaction between efavirenz and simvastatin (Zocor) or atorvastatin (Lipitor).
In Positively Aware, from Test Positive Aware Network
- Neurologic Side Effects of Efavirenz Not Affected by the Drug's Blood Levels (March/April 2004)
In Positively Aware, from Test Positive Aware Network
- Substudy of 2NN Shows Nevirapine and Efavirenz to Be Equal in Potency (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- NNRTI Therapy Associated With Better Sexual Satisfaction (January 6, 2004)
From aidsmap.com
- Mother-to-Child Transmission: How Will AZT and Nevirapine Use for MTCT Affect Future Treatment? (Winter 2003/2004)
To read PDF, click here
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Efavirenz or Nevirapine Regimens Are More Potent Than Trizivir for Initial Therapy (September 15, 2003)
A 100-patient Spanish study confirms the findings of ACTG 5095.
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- No Detectable Difference in Efficacy Seen Between Efavirenz and Nevirapine (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Treatment Regimens Containing Efavirenz, Nevirapine or Kaletra Are the Most Potent Options for Patients Starting Therapy (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Trizivir Plus Efavirenz Potent for Naive Patients With Low CD4 Counts and High Viral Loads (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients With Human Immunodeficiency Virus Infection (September 11, 2003)
In The New England Journal of Medicine
- A Randomized Trial of 2 Different 4-Drug Antiretroviral Regimens Versus a 3-Drug Regimen, in Advanced Human Immunodeficiency Virus Disease (September 1, 2003)
Patients with advanced HIV are found to benefit the most from HAART regimens containing efavirenz (Sustiva), as opposed to regimens containing nelfinavir (Viracept) or no NNRTI at all.
In Journal of Infectious Diseases
- Low-Level Resistance and Minority Populations: Cross-Resistance Between Nevirapine and Efavirenz (August/September 2003)
Once an NNRTI-based regimen fails, no other NNRTIs will work any better, two studies suggest.
In Treatment Bulletin, from HIV i-Base
- Little Lipodystrophy Seen With Either Atazanavir or Efavirenz (July 16, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- ACTG 5095: Efavirenz-Based Regimens Outperform Triple Nucleoside Combination (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- ACTG 5097s: Efavirenz-Related CNS Events in the 5095 Study (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Another Look at Induction Maintenance Therapy (July 14, 2003)
48-week data on Trizivir and efavirenz in treatment-naive patients.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Better Suppression, Adherence With Once-Daily FTC/ddI/Efavirenz Than Most PI-Based Regimens (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Efavirenz-Based HAART Outperforms a Triple Nucleoside Regimen in Clinical Practice (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- IATEC Presents the 2NN Study Results (July 14, 2003)
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
- Nevirapine- Versus Efavirenz-Containing Three-Drug Regimens (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- The Buzz: Anatomy of a Study -- Trizivir vs. Sustiva (May/June 2003)
A closer look at ACTG 5095, which examined the use of Trizivir and efavirenz in several first-line treatment regimens.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Efavirenz More Durable Than Nevirapine, But CNS Toxicity Underestimated (April 29, 2003)
British researchers find that efavirenz works better over the long term, but that its psychiatric side effects persist a lot longer than previously thought.
From aidsmap.com
- Who Won 2NN? You (April 2003)
A summary of the 2NN study presented at CROI 2003.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Trizivir-Only Arm Closed in PI-Sparing, Naive Therapy Trial (March 10, 2003)
Important interim results from a Phase III, randomized, double-blind comparison of three protease-inhibitor-sparing regimens for the initial treatment of HIV infection (AACTG Protocol A5095).
To read PDF, click here
From U.S. National Institute of Allergy and Infectious Diseases
- Results of the 2NN Study: A Randomized Comparative Trial of First-Line Antiretroviral Therapy With Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together With Stavudine and Lamivudine (February 14, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Lipid Changes in a Randomized Comparative Trial of First-Line Antiretroviral Therapy With Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together With Stavudine and Lamivudine (2NN Study) (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Research From the 42nd ICAAC: Atazanavir (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Research From the 42nd ICAAC: Two PIs vs. Two PIs vs. Efavirenz (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Shift in HIV-1 Resistance After Treatment Interruption in Patients With Virological Failure and Antiviral Effect Following Trizivir Plus Efavirenz (AZLF3003 Study) (November 19, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Prospective Study of Regional Body Composition in Antiretroviral-Naive Subjects Randomized to Receive Zidovudine + Lamivudine or Didanosine + Stavudine Combined With Nelfinavir, Efavirenz or Both: A5005s, a Substudy of ACTG 384 (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- Efavirenz Long-Term Side Effects (August 9, 2002)
From Canadian AIDS Treatment Information Exchange
- Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Stavudine When Used in Combination With Lamivudine and Efavirenz in HIV-1 Infected Patients Naive to Antiretroviral Therapy: 48-Week Interim Results (July 12, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Switching Protease Inhibitors to Nevirapine, Efavirenz or Abacavir: A Randomized, Multicenter, Open-Label, Simplification Trial (July 10, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Abacavir/Lamivudine in Combination With Efavirenz, Amprenavir/Ritonavir or Stavudine: ESS40001 (CLASS) Preliminary 48-Week Results (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Resistance Profiles at Baseline and Following Virologic Failure for Subjects Randomized to Receive Abacavir/Efavirenz/Didanosine +/-; Hydroxyurea After Failing Initial NRTI +/- PI Therapy (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Quality of Life, Emotional Status, and Adherence of HIV-1-Infected Patients Treated With Efavirenz Versus Protease Inhibitor-Containing Regimens (April 15, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Switching Protease Inhibitors to Nevirapine (NEV), Efavirenz (EFA) or Abacavir (ABA): A Randomized, Multicenter, Open-Label, Simplification Trial (February 28, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- An Assessment of Plasma Amprenavir (APV) Pharmacokinetics (PK) Following Administration of Two GW433908 (908) and Ritonavir (RTV) Regimens in Combination With Efavirenz (EFV) in Healthy Adult Subjects (APV10010) (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- A Randomized Trial of Metabolic and Body Composition Changes in Patients Switching from PI-Containing Regimens to Abacavir (ABC), Efavirenz (EFV) or Nevirapine (NVP) (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- ACTG 388 Results Indicate Efavirenz-Containing Regimen Superior (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Efavirenz Helps Get Rid of Kaposi's Sarcoma (February 14, 2002)
From Canadian AIDS Treatment Information Exchange
- Birth Defect in Baby Born to Efavirenz User (February 6, 2002)
From Canadian AIDS Treatment Information Exchange
- Virologic Response to Abacavir/Efavirenz/ddI + Hydroxyurea in Subjects Failing Initial NRTI + PI Therapy (NZTA4008 Study) (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Once-Daily Combination Therapy with Emtricitabine, Didanosine and Efavirenz in Treatment-Naive HIV-Infected Adults: 24-Month Follow-Up of the ANRS 091 Trial (October 30, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Lack of Clinically Relevant Drug-Drug Interactions Between Tenofovir DF and Efavirenz, Indinavir, Lamivudine and Lopinavir/Ritonavir in Healthy Subjects (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Minor Interaction Between Efavirenz and Saquinavir When Combined With Small Doses of Ritonavir in a QD Regimen (October 28, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- The Compact Quad, Combivir/Abacavir/Efavirenz -- Preliminary 48-Week Results (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Nelfinavir, Efavirenz, or Both After the Failure of Nucleoside Treatment of HIV Infection (August 9, 2001)
In New England Journal of Medicine
- Does Efavirenz (Sustiva) Cause Breast Enlargement? (August 1, 2001)
From Canadian AIDS Treatment Information Exchange
- Genetic Correlates of Phenotypic Hypersusceptibility to Efavirenz (EFV) in Highly Nucleoside-Experienced Subjects in ACTG 364 (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Efavirenz (EFV)-Containing Antiretroviral (ARV) Therapy (T) Effectively Reduces HIV RNA in the Seminal Plasma (SP) of HIV-1-Infected Men (M) (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Pharmacologic Characteristics of Efavirenz and Nelfinavir Associated With Virologic Response in HIV-Infected Children (February 5, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Successful Substitution of Protease Inhibitors With Efavirenz (EFV) in Patients With Undetectable Viral Loads -- A Prospective, Randomized, Multicenter, Open-Label Study (DMP 049) (February 5, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Evaluation of Novel Combination of Abacavir, Lamivudine and Efavirenz (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
- PROTRA Study: To Evaluate the Safety and Efficacy of Abacavir and Efavirenz When Substituted for a PI in HIV-1-Infected Subjects Treated With Two NRTIs and a PI With Plasma HIV-RNA Levels Below the Limit of Assay Quantification (July 11, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Therapeutic Drug Monitoring of Amprenavir Combined With Ritonavir as Salvage Therapy in HIV-1-Infected Patients (July 11, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Efficacy of Efavirenz (Sustiva) Concerning Regimens in Patients With Baseline Plasma HIV-1 RNA Viral Load Exceeding 100,000 copies/mL (February 2, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Summary of Pharmacokinetic Drug Interaction Studies With Efavirenz (November 14, 1998)
In The 36th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Study Shows Efavirenz Promising in Treating Pediatric HIV Infection (September 28, 1998)
Leads to approval of new drug for treating HIV-infected children.
From U.S. National Institute of Allergy and Infectious Diseases
- Efavirenz (Sustiva™) May Equal or Exceed Protease Inhibitor in Initial Antiretroviral Combination (July 17, 1998)
From AIDS Treatment News
- A Phase III, Double-Blind, Placebo-Controlled, Multi-Center Study to Determine the Effectiveness and Tolerability of the Combination of Efavirenz and Indinavir (IDV) Versus Indinavir in HIV-1 Infected Patients Receiving Nucleoside Analogue (NRTI) Therapy (June 30, 1998)
In The 12th International AIDS Conference, from The Body PRO
- More on Efavirenz (June 30, 1998)
In The 12th International AIDS Conference, from The Body PRO
- Still More on Efavirenz (June 30, 1998)
In The 12th International AIDS Conference, from The Body PRO
- Durable Clinical Anti-HIV-1 Activity (72 Weeks) and Tolerability for Efavirenz (DMP 266) in Combination With Indinavir (IDV) (June 29, 1998)
In The 12th International AIDS Conference, from The Body PRO
- Efavirenz (Sustiva, DMP 266) and Saquinavir (Fortovase) Combination: Pharmacologic Interaction (June 5, 1998)
From AIDS Treatment News
- Efavirenz + Indinavir (February 4, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- DMP-266 Resistance, Interactions, and Clinical Efficacy (September 28-October 1, 1997)
In The 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Efavirenz (SUSTIVA, Formerly DMP-266) 48-Week Data Announced (September 19, 1997)
From AIDS Treatment News
- Impact of DMP-266, A New, Unapproved NNRTI, With Indinavir, and D4T (September 1997)
In The 35th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
Nevirapine (Viramune)
- High LDL Cholesterol Levels May Drop by Switching Sustiva to Viramune, Study Says (June 12, 2007)
From AIDSMeds.com
- Nevirapine-Associated Toxicity Less Frequent in Non-Naive Patients (August 17, 2006)
In XVI International AIDS Conference
- Hepatotoxicity in IDUs and Non-IDUs Receiving Nevirapine-Based HAART (August 16, 2006)
In XVI International AIDS Conference
- Nevirapine Resistance May Persist in Some Pregnant Women, Study Finds (May 3, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- In Uganda, Three-NRTI Regimen Including Abacavir Is Better Tolerated Than Nevirapine-Based Regimen (February 7, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- HIV JournalView: Dosing Adjustment Likely Needed for Statins Taken With NNRTIs (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- More Questions Than Answers Regarding High Hepatic Event Rates Among Thai Patients in 2NN Study (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Therapeutic Drug Monitoring Study Finds Adequate Drug Levels for Once-Daily Nevirapine (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- The Relevance of Host Genotype on Nevirapine Drug Levels (February 23, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Warning on Two Specific 3-Drug Regimens: Viread + Videx + Either Sustiva or Viramune (November 23, 2004)
A brief comment on the recently issued warning that both regimens frequently fail.
In AIDS Treatment News, from AIDS Treatment News
- Addition of Short-Course Zidovudine/Lamivudine to Single-Dose Nevirapine Decreases Development of Maternal NNRTI-Resistant HIV (July 15, 2004)
In The XV International AIDS Conference, from The Body PRO
- A HAART Regimen With Lower Metabolic Effect: Nevirapine Plus Non-Thymidine Analog NRTIs (July 14, 2004)
In The XV International AIDS Conference, from The Body PRO
- Confort Study Supports Switch From Protease Inhibitor to Nevirapine (July 14, 2004)
In The XV International AIDS Conference, from The Body PRO
- HDL Benefit Is Maintained With Extension of Nevirapine and Efavirenz Treatment in 2NN Study (July 14, 2004)
In The XV International AIDS Conference, from The Body PRO
- Pregnancy: Severe Liver Toxicity in Nevirapine-Based HAART (June 21, 2004)
From aidsmap.com
- Washington Post Profiles South African Program Using Nevirapine to Reduce Risk of Mother-to-Child HIV Transmission (June 9, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Efavirenz and Nevirapine Keep Going, and Going and Going ... (March/April 2004)
Efavirenz and nevirapine may persist in the body longer than was originally thought according to two studies presented at CROI 2004.
In Positively Aware, from Test Positive Aware Network
- Nevirapine Well Tolerated in HIV-Infected Pregnant Women (February 11, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Substudy of 2NN Shows Nevirapine and Efavirenz to Be Equal in Potency (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Nevirapine Should Not Be Used for PEP, Confirms U.S. Review (February 2, 2004)
From aidsmap.com
- Nevirapine Hepatotoxicity Risks Clarified in New Letter to Healthcare Professionals (PDF) (February 2004)
From Boehringer Ingelheim
- NNRTI Therapy Associated With Better Sexual Satisfaction (January 6, 2004)
From aidsmap.com
- Mother-to-Child Transmission: How Will AZT and Nevirapine Use for MTCT Affect Future Treatment? (Winter 2003/2004)
To read PDF, click here
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- NNRTI-Based HAART Associated With Quicker CD4 Cell Gains Than PI-Based Therapy (November 13, 2003)
Most of the patients in this large but non-randomized Canadian study were taking nevirapine (Viramune).
In The XIII International AIDS Conference, from aidsmap.com
- Efavirenz or Nevirapine Regimens Are More Potent Than Trizivir for Initial Therapy (September 15, 2003)
A 100-patient Spanish study confirms the findings of ACTG 5095.
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- No Detectable Difference in Efficacy Seen Between Efavirenz and Nevirapine (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Switching From PI to Nevirapine in Patients With Undetectable Viral Load Is Safe and Potent (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Treatment Regimens Containing Efavirenz, Nevirapine or Kaletra Are the Most Potent Options for Patients Starting Therapy (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Nevirapine Reduced Mother-to-Child Transmission Better Than AZT -- At 70 Times Less Cost (September 12, 2003)
In AIDS Treatment News, from AIDS Treatment News
- Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients With Human Immunodeficiency Virus Infection (September 11, 2003)
In The New England Journal of Medicine
- Scientists in Uganda Dismiss South African Claims About Safety, Efficacy of Nevirapine (August 19, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Higher Than Recommended Dose of Nevirapine Needed for HIV Suppression in Children (August 7, 2003)
From aidsmap.com
- Low-Level Resistance and Minority Populations: Cross-Resistance Between Nevirapine and Efavirenz (August/September 2003)
Once an NNRTI-based regimen fails, no other NNRTIs will work any better, two studies suggest.
In Treatment Bulletin, from HIV i-Base
- IATEC Presents the 2NN Study Results (July 14, 2003)
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
- Nevirapine- Versus Efavirenz-Containing Three-Drug Regimens (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Switch to Nevirapine From Protease Inhibitor Lowers Triglycerides and Maintains Viral Load Suppression (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Does Viramune = Sustiva? (May/June 2003)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Efavirenz More Durable Than Nevirapine, But CNS Toxicity Underestimated (April 29, 2003)
British researchers find that efavirenz works better over the long term, but that its psychiatric side effects persist a lot longer than previously thought.
From aidsmap.com
- Who Won 2NN? You (April 2003)
A summary of the 2NN study presented at CROI 2003.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Nevirapine Studied as Pre-Exposure Prophylaxis for HIV (February 25, 2003)
Early trials suggest a low dose of the drug may be safely used in HIV prevention.
From aidsmap.com
- Results of the 2NN Study: A Randomized Comparative Trial of First-Line Antiretroviral Therapy With Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together With Stavudine and Lamivudine (February 14, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Lipid Changes in a Randomized Comparative Trial of First-Line Antiretroviral Therapy With Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together With Stavudine and Lamivudine (2NN Study) (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Nevirapine Patient Assistance Program: Model for Better Administration? (November 22, 2002)
In AIDS Treatment News, from AIDS Treatment News
- Ethiopia Ready to Start Nevirapine Trials for AIDS Treatment (November 20, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Nevirapine and Vivid Dreams (September 12, 2002)
From Canadian AIDS Treatment Information Exchange
- Nevirapine During Labor and in the Neonate Significantly Improves Zidovudine Prophylaxis for the Prevention of Perinatal HIV Transmission: Results of PHPT-2 First Interim Analysis (July 12, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Promoting Prevention of Mother-to-Child Transmission of HIV Through the Viramune Donation Programme: A Model of Public-Private Partnership (July 10, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Switching Protease Inhibitors to Nevirapine, Efavirenz or Abacavir: A Randomized, Multicenter, Open-Label, Simplification Trial (July 10, 2002)
In The XIV International AIDS Conference, from The Body PRO
- WHO and UNAIDS Continue to Support Use of Nevirapine for Prevention of Mother-to-Child HIV Transmission (March 22, 2002)
From UNAIDS
- Switching Protease Inhibitors to Nevirapine (NEV), Efavirenz (EFA) or Abacavir (ABA): A Randomized, Multicenter, Open-Label, Simplification Trial (February 28, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- CHARM: A Phase III Open-Label, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of Adding Nevirapine and/or Hydroxyurea to a Triple Nucleoside-Based Antiretroviral Drug Regimen in Treatment-Naïve HIV-1-Infected Subjects (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Effect of Nevirapine (NVP) for Perinatal HIV Prevention Appears Greatest Among Women With Most Advanced Disease: Subgroup Analyses of HIVNET 012 (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- A Randomized Trial of Metabolic and Body Composition Changes in Patients Switching from PI-Containing Regimens to Abacavir (ABC), Efavirenz (EFV) or Nevirapine (NVP) (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Nevirapine and Protease Inhibitor-Based Regimens in a Directly Observed Therapy (DOT) Program for Intravenous Drug Users (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Comparison of Nevirapine Resistance Mutations in Women vs. Infants Receiving Single Dose NVP Prophylaxis to Prevent HIV-1 Vertical Transmission (HIVNET 012) (December 16, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Nevirapine Notes (November 2001)
In HIV Treatment ALERTS!, from The Center for AIDS
- Long-Term Follow-Up of Antiretroviral-Naive HIV-Infected Patients Treated with d4T and ddI (QD) and Nevirapine (BID or QD) in the VIRGO Study (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Rise in HDL Cholesterol Associated With Nevirapine Containing Antiretroviral Therapy in HIV-1 Infected Patients Is Sustained Over 48 Weeks of Treatment (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- A Retrospective Cohort Study of the Durability of Antiretroviral Therapy Using Nevirapine versus Antiretroviral Therapy Using Protease Inhibitors (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Retrospective Review of Nevirapine-Induced Hepatotoxicity in HIV/HCV Co-Infected Patients in a Community Health Center (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Impact of HIV-1 Subtype on Women Receiving Single Dose Nevirapine Prophylaxis to Prevent HIV-1 Vertical Transmission (October 2, 2001)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Study Finds Women More Likely to Get Rash With Nevirapine Than Men (August 16, 2001)
From Canadian AIDS Treatment Information Exchange
- Metabolic and Anthropometric Changes Observed in HIV-Infected Patients Treated With Combivir (ZDV/3TC) Plus Nelfinavir or Nevirapine (A Substudy of the COMBINE Study) (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Nevirapine-Containing Antiretroviral Therapy in HIV-1-Infected Patients Results in an Anti-Atherogenic Lipid Profile (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Switching Protease Inhibitor (PI) to Nevirapine (NVP) Leads to a Better Lipid Profile Than Switch to Efavirenz (EFV) (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Final 12-Month Results From the COMBINE Study: A Randomized, Open, Multicenter Trial Comparing Combivir Plus Nelfinavir or Nevirapine in Naive Patients (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Nevirapine Containing Potent Antiretroviral Therapy Results in Ananti-Atherogenic Plasma Lipid Profile: Results From the Atlantic Trial (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Pharmacologic Characteristics of Efavirenz and Nelfinavir Associated With Virologic Response in HIV-Infected Children (February 5, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Adverse Effects Associated With Use of Nevirapine in HIV Postexposure Prophylaxis for Two Health Care Workers (December 6, 2000)
In Journal of the American Medical Association Research Letter
- More Data on the Comparative Efficacy of Protease Inhibitors Versus Non-nukes (October 10, 2000)
STEP's coverage of the 40th ICAAC Conference.
In STEP Ezine, from Seattle Treatment Education Project
- Inexpensive AIDS Drug Still Reduces HIV Transmission from Mother to Child After One Year (July 13, 2000)
From U.S. National Institute of Allergy and Infectious Diseases
- Sustained Virologic Suppression in Subjects Switched From Protease Inhibitors to Nevirapine (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Studies Suggest Nevirapine Can Be Dosed Either Once or Twice Daily; Effective at Both High and Low Viral Loads (July 11, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Viramune Affects Birth Control in HIV+ Women (March 31, 2000)
In STEP Ezine, from Seattle Treatment Education Project
- Selected Highlights From the 7th CROI: Nevirapine (Viramune) Plus AZT and 3TC (Spring 2000)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Nevirapine: One-Year Combination Results Published (April 3, 1998)
In AIDS Treatment News, from AIDS Treatment News
- Nevirapine Plus Two Nucleosides Exerts Durable Effect (April 1998)
In HIV Newsline, from San Francisco General Hospital
- Oral Contraceptive / Nevirapine Interaction Trial (March 6, 1998)
In AIDS Treatment News, from AIDS Treatment News
- Nevirapine Protects Chimpanzee Against HIV-1 Infection (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
|
|
